Autism Spectrum Disorder Trial, Recruiting NCT05419895 Sponsor: Emory University Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT05419895
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The child must be between 16 and 30 months old and have scored 8 or higher on a standard early autism screening tool called the M-CHAT-R.
  • The child must have been referred to the clinic by a healthcare provider who is part of one of the participating BCW (Baby's Can't Wait) health districts in this pilot study, and the referral must happen before the child turns 33 months old.
  • The evaluation must take place before the child turns 36 months old.
  • The parent or guardian must have a basic ability to communicate in English.
  • The parent or guardian must have access to the internet.
  • The child must have some regular exposure to English, either at home or in a childcare or similar setting.
  • The referral paperwork must include documentation of the child's M-CHAT-R score of 8 or higher.

Who may not be able to join:

  • Families who refer themselves to the clinic, or who are referred from healthcare providers outside of the designated BCW districts, are not eligible for this study.
  • Children who are already older than 33 months at the time of referral are not eligible, as the current study approach has not yet been developed for children over this age.
  • Families where English is not spoken are not eligible for this phase of the study, as the current program is designed around English language use.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Allison Schwartz, PhD, Emory University

Phone: 404.727.8350

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
16 June 2022
Est. completion
1 July 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants referred to the Early Diagnostic Response Model (EDRM); Number of participants consented in the Early Diagnostic Response Model (EDRM) study; Response rate in the Early Diagnostic Response Model (EDRM) study; Number of participants that completed the Early Diagnostic Response Model (EDRM) study; Time from referral to completion of the program

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov